Polaris Market Research today announced findings from its latest report, projecting the global antiparasitic drugs market to grow from USD 3.01 billion in 2024 to USD 4.4 billion by 2034, at a CAGR of 4.40%. The report profiles 15 leading companies across three market segments, covering type, route of administration, and distribution channel.

Analyst Commentary on Antiparasitic Drugs Market Growth

“Global health initiatives targeting malaria, leishmaniasis, and helminth infections are creating steady, dependable demand for antiparasitic therapies, especially in regions where these diseases remain a daily public health burden,” said an analyst at Polaris Market Research. “The opportunity for manufacturers now lies in improving formulations and delivery methods that can better address drug resistance, which remains one of the field’s toughest ongoing challenges.”

Antiparasitic Drugs Market Statistics at a Glance

• 2024 Market Size: USD 3.01 Billion
• 2025 Projected Size: USD 3.1 Billion
• 2034 Projected Size: USD 4.4 Billion
• CAGR (2025–2034): 4.40%
• Largest Region (2024): North America
• Report Coverage: 130 pages, historical data 2020–2023, forecast period 2025–2034

Market Context: Global Health Priorities Drive Steady Demand

Antiparasitic drugs treat infections caused by protozoa and helminths, conditions such as malaria, leishmaniasis, and various worm infestations that remain widespread in tropical and subtropical regions. Population growth, demographic shifts, and urbanization all influence susceptibility to parasitic infections, sustaining broad-based demand across age groups and geographies. Pharmaceutical research continues to advance the category, with new formulations and delivery systems aimed at improving efficacy, reducing drug resistance, and easing patient adherence. In March 2022, May & Baker Nigeria Plc, a leading Nigerian pharmaceutical company, introduced a new medication targeting malaria parasites nationwide, illustrating how regional manufacturers are responding directly to local disease burden.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/antiparasitic-drugs-market

Key Growth Drivers, Major Companies and Segments Covered

Growth Drivers: Global health initiatives targeting malaria, leishmaniasis, and helminth infections, alongside the sustained prevalence of parasitic disease in tropical regions, are the primary forces behind the market’s expansion. In January 2025, Ghana launched a community-wide mass drug administration program using moxidectin for river blindness, distributing 250,000 six-monthly doses following FDA approval in 2024, while research published the same month found that adding a monthly antimalarial course to daily co-trimoxazole reduced malaria risk by 68% in HIV-positive pregnant women across Sub-Saharan Africa.

Major Companies Covered: AstraZeneca, Bayer AG, Cipla Limited, Dr. Reddy’s Laboratories, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Ipca Laboratories Ltd, Lupin Pharmaceuticals, Merck & Co., Novartis, Pfizer, Sanofi, Sun Pharmaceutical Industries Ltd., Viatris, and Zydus Group.

Segments Covered: By Type (Antiprotozoals, Anthelmintics, Others), By Route of Administration (Topical, Oral, Injectable), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Others).

Recent Developments in the Antiparasitic Drugs Market

• April 2025: Appili Therapeutics achieved FDA alignment on NDA requirements for ATI-1801, a topical paromomycin-based therapy for cutaneous leishmaniasis, positioning the product for submission later in 2025.
• February 2025: DNDi released a regional elimination framework for visceral leishmaniasis in Eastern Africa, emphasizing integrated vector management and early diagnosis.
• January 2025: Ghana initiated a mass drug administration program using moxidectin for river blindness, distributing 250,000 doses nationwide.

Segment Snapshot: Anthelmintics and Injectables Lead, Asia Pacific Fastest-Growing

Anthelmintics accounted for a significant share of the market in 2024, reflecting their central role in treating helminthic infections across both medical and veterinary applications by disrupting the physiological processes of parasitic worms. Injectable formulations held a significant share of the route-of-administration segment, valued for rapid, precise dosing in severe cases where oral treatment is impractical, while hospital pharmacies led the distribution channel segment given their central role in prescribing and dispensing treatment for diagnosed patients. Regionally, North America dominated in 2024 on the strength of its healthcare infrastructure and R&D investment, while Asia Pacific is expected to see the most significant growth as the region’s varied disease burden — spanning malaria, leishmaniasis, and helminthiasis — drives demand for tailored pharmacological therapies.

Why It Matters for Buyers Evaluating Global Health Supply Chains

For stakeholders researching antiparasitic therapeutics for public health programs, hospital procurement, or pharmaceutical R&D, the underlying report benchmarks antiparasitic drugs  market share, company positioning, and segment-level forecasts to support sourcing, partnership, and investment decisions through 2034. With Asia Pacific’s disease burden driving regional growth and drug resistance remaining a persistent challenge, the report maps where innovation and demand are converging.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

high-purity-silica-sand-for-solar-cell-market

reclaimed-rubber-from-devulcanization-market

automotive-lead-acid-battery-market

automotive-brake-systems-market

us-ethylene-market

synthetic-data-in-market-research-promise-pitfalls-and-what-analysts-need-to-know

https://www.polarismarketresearch.com/press-releases/artificial-intelligence-market

gypsum-market

solid-state-drive-market